Clinical trials: Short Bowel Syndrome
Short Bowel Syndrome
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
- Trial name
- EASE SBS 1 (NCT03690206)
- Testing
- glepaglutide
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 106 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
- Trial name
- STARS extend (NCT05018286)
- Testing
- Apraglutide
- Where
- 66 sites in United States, Argentina and 16 more
- Volunteers
- 158 people
- Sponsor
- VectivBio AG
Short Bowel Syndrome
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.
- Trial name
- STARSnutrition (NCT04964986)
- Testing
- Apraglutide
- Where
- 2 sites in Belgium, France
- Volunteers
- 10 people
- Sponsor
- VectivBio AG
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Short Bowel Syndrome, Intestinal Fistula
Intralipid Versus SMOFlipid in HPN Patients
This study will randomize all patients who are new to the Mayo Clinic HPN team to either standard lipid emulsion (Intralipid) or SMOFLipid.
- Conditions
- Short Bowel Syndrome, Intestinal Fistula, Crohn Disease, Intestinal Obstruction
- Trial name
- NCT03773237
- Testing
- SMOFLipid, Intralipid
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Short Bowel Syndrome (SBS)
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in…
- Trial name
- NCT05371028
- Testing
- Non-interventional Study
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Takeda
Short Bowel Syndrome
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
This study will follow participants who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric participants with Short Bowel Syndrome (SBS).
- Trial name
- NCT02954458
- Testing
- TED, SOC, Syringe
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 61 people
- Sponsor
- Shire
Short Bowel Syndrome
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period.
- Trial name
- NCT02949362
- Testing
- Teduglutide, SOC
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Shire
Short Bowel Syndrome
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.
- Trial name
- STARS (NCT04627025)
- Testing
- apraglutide
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 164 people
- Sponsor
- VectivBio AG
Short Bowel Syndrome
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS).
- Trial name
- EASE SBS 4 (NCT04991311)
- Testing
- Glepaglutide
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
Sarcopenia and Short Bowel Syndrome
Sarcopenia or the loss of skeletal muscle is highly prevalent in many diseases, including short bowel syndrome (SBS). While adaptation is more likely in SBS patients with a colon-in-continuity, the consequences and underlying…
- Trial name
- SARCO-SGC (NCT05441345)
- Testing
- questionnaires with collection of stool and urine
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Short Bowel Syndrome
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
Part A:once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and…
- Trial name
- NCT03415594
- Testing
- FE203799 GLP-2 analogue
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- GlyPharma Therapeutics
SBS - Short Bowel Syndrome
Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency
This is a repeated dose, open label trial investigating safety, efficacy, PD and PK of FE 203799 in 8 patients with SBS. The patients will receive a subcutaneous (SC) dose of 5 mg FE 203799 once weekly for 4 consecutive weeks…
- Trial name
- NCT03408132
- Testing
- FE203799
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- GlyPharma Therapeutics
Short Bowel Syndrome
MENDD Tolerance Assessment Study
This study will utilize approved devices in an off-label manner to create forces required to induce intestinal lengthening. Radial and longitudinal forces are both required, and two devices will be used to create forces in order…
- Trial name
- NCT06185088
- Testing
- Coda® Balloon Catheters, Double Balloon Endoscope (DBE)
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome
Cholestasis Reversal: Efficacy of IV Fish Oil
The purpose of this study is to determine whether Omegaven is effective in the treatment of parenteral nutrition associated liver disease (PNALD).
- Conditions
- Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome, Gastrointestinal Disease
- Trial name
- Reversal (NCT00910104)
- Testing
- Omegaven®
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mark Puder
Short Bowel Syndrome, Infection, Bacterial
Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome
The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.
- Trial name
- GRAAL (NCT05302531)
- Testing
- Amoxicillin, Levofloxacin, Ofloxacin
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Central Hospital, Nancy, France
Short Bowel Syndrome
A Study of PJ009 in Healthy Adult Volunteers
The main aim of this clinical trial is to assess the safety of PJ009 in healthy adult volunteers aged 18-45. The main questions it aims to answer are: Is PJ009 safe in healthy adult? Participants will Receive single dose of PJ009…
- Trial name
- NCT06523101
- Testing
- PJ009
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Central Line Complication, Central Line Infection
Innovative Central Line Securement Device in the Pediatric Population
This study involves evaluating pediatric patients with central lines to determine differences in line complications and quality of life in those with a novel central line securement device (wrap) as compared to those who use a…
- Conditions
- Central Line Complication, Central Line Infection, Central Line-Associated Infection, Central Line Sepsis
- Trial name
- NCT04522778
- Testing
- Wearable Central Line Securement Device (Vest), Traditional Securement Dressing
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ryan St. Pierre-Hetz
Short Bowel Syndrome, Parenteral Nutrition Associated Liver Disease
Study of NST-6179 in Healthy Subjects
A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.
- Trial name
- NCT05181085
- Testing
- NST 6179
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Intestinal Pseudo-Obstruction, Short Bowel Syndrome
Improved Quality of Life in Children With Intestinal Failure
Children with intestinal failure have a lack of tolerance for food in the intestine. The children are dependent on intravenous nutrition over a long period of time period to ensure growth and development.
- Conditions
- Intestinal Pseudo-Obstruction, Short Bowel Syndrome, Malabsorption Syndrome Autoimmune Enteropathy, Bacterial Overgrowth
- Trial name
- NCT04981262
- Testing
- Stimulance
- Where
- Norway
- Volunteers
- 56 people
- Sponsor
- Oslo University Hospital